BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Pseudomonas infection
,
Kidney
,
Holistic medicine
,
Doxycycline
,
rs3825942
,
MDM2
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
pim1 protein, human
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Cord blood mononuclear cells depleted of PIM kinases under Th1 or Th2 polarizing conditions
Cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal
Multiple myeloma MM.1S and U266 cells treated with PIM2 kinase inhibitor JP11646
Secondary AML cells treated with ARV-825, a BET-domain proteolysis-targeting chimera (BET-PROTAC)
Monocytes CD14+ from the blood of active or inactive Adult Still's disease (ASD) patients
Explore Curated Studies Results
Literature
Most Relevant Literature
Kinase PIM1 governs ferroptosis to reduce retinal microvascular endothelial cell dysfunction trigger…
PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses …
PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the End…
The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their…
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B A…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ